Concepedia

Mark Seierstad

MS

25

Publications

901

Citations

18

H-Index

1999

Active since

Affiliations

Janssen (United States)(Current)

Johnson & Johnson (United States)

University of Minnesota

Janssen (Belgium)

University of Illinois Urbana-Champaign

Mark Seierstad is an author at Janssen (United States) specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

1999–2024

25

Publications

25

R3(BΔ23–27)R/I5 Chimeric Peptide, a Selective Antagonist for GPCR135 and GPCR142 over Relaxin Receptor LGR7

Chester Kuei, Steven W. Sutton, Pascal Bonaventure et al. · Journal of Biological Chemistry · 2007 · 137 citations · Full text

Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase

John M. Keith, Richard L. Apodaca, Wei Xiao et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 91 citations · Full text

, , +3

A QSAR Model of hERG Binding Using a Large, Diverse, and Internally Consistent Training Set

Mark Seierstad, Dimitris K. Agrafiotis · Chemical Biology & Drug Design · 2006 · 82 citations · Full text

, , +21

Design Optimization of 1,3-Diphospha-2,4-diboretane Diradicals

Mark Seierstad, Christopher R. Kinsinger, Christopher J. Cramer · Angewandte Chemie International Edition · 2002 · 59 citations

, , +10

Preclinical Characterization of the FAAH Inhibitor JNJ-42165279

John M. Keith, W. M. Jones, Mark S. Tichenor et al. · ACS Medicinal Chemistry Letters · 2015 · 59 citations · Full text

, , +15

Rows per page

1–5 of 25